Billiontoone (NASDAQ:BLLN) CTO David Tsao Sells 10,000 Shares of Stock

Billiontoone, Inc. (NASDAQ:BLLN) CTO David Tsao sold 10,000 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $92.86, for a total transaction of $928,600.00. Following the completion of the sale, the chief technology officer owned 1,000 shares of the company’s stock, valued at approximately $92,860. This represents a 90.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Tsao also recently made the following trade(s):

• On Monday, June 15th, David Tsao sold 20,000 shares of Billiontoone stock. The stock was sold at an average price of $102.27, for a total value of $2,045,400.00.

Billiontoone Stock Performance

BLLN stock opened at $97.45 on Thursday. Billiontoone, Inc. has a 1-year low of $61.96 and a 1-year high of $150.44. The company has a current ratio of 11.69, a quick ratio of 11.31 and a debt-to-equity ratio of 0.17. The firm has a market cap of $4.48 billion and a PE ratio of 139.21. The business’s 50-day moving average price is $116.70 and its two-hundred day moving average price is $94.55.

Billiontoone (NASDAQ:BLLN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.15 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.15. The company had revenue of $109.45 million during the quarter. Billiontoone had a return on equity of 9.96% and a net margin of 8.04%. As a group, research analysts forecast that Billiontoone, Inc. will post 0.83 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on BLLN. Wall Street Zen downgraded Billiontoone from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. BTIG Research decreased their target price on Billiontoone from $142.00 to $130.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. JPMorgan Chase & Co. dropped their price target on Billiontoone from $145.00 to $130.00 and set an “overweight” rating on the stock in a research note on Thursday, August 6th. Weiss Ratings raised Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. Finally, Guggenheim began coverage on shares of Billiontoone in a research report on Monday, June 29th. They set a “buy” rating and a $125.00 price objective for the company. Six investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $126.71.

Institutional Investors Weigh In On Billiontoone

A number of institutional investors have recently made changes to their positions in BLLN. Massachusetts Financial Services Co. MA acquired a new position in shares of Billiontoone in the fourth quarter valued at approximately $13,373,000. Baillie Gifford & Co. bought a new position in shares of Billiontoone during the fourth quarter worth approximately $103,786,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Billiontoone during the 4th quarter worth approximately $1,348,000. UBS Group AG acquired a new stake in Billiontoone during the 4th quarter worth approximately $2,586,000. Finally, Renaissance Capital LLC bought a new stake in Billiontoone in the 4th quarter valued at $201,000.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.